Australia markets open in 8 hours 39 minutes

Monopar Therapeutics Inc. (MNPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3400+0.0160 (+4.94%)
At close: 03:59PM EST
0.3759 +0.03 (+8.96%)
Pre-market: 09:12AM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 5.05M
Enterprise value -3.44M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.76
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.35

Trading information

Stock price history

Beta (5Y monthly) 0.77
52-week change 3-87.02%
S&P500 52-week change 314.78%
52-week high 33.8200
52-week low 30.2740
50-day moving average 30.4283
200-day moving average 31.0128

Share statistics

Avg vol (3-month) 3962.77k
Avg vol (10-day) 3103.16k
Shares outstanding 514.87M
Implied shares outstanding 614.87M
Float 85.77M
% held by insiders 168.00%
% held by institutions 11.67%
Shares short (14 Nov 2023) 4187.81k
Short ratio (14 Nov 2023) 40.07
Short % of float (14 Nov 2023) 42.93%
Short % of shares outstanding (14 Nov 2023) 41.26%
Shares short (prior month 12 Oct 2023) 446.05k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-53.33%
Return on equity (ttm)-99.20%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-9.48M
Diluted EPS (ttm)-0.7200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.49M
Total cash per share (mrq)0.57
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.32
Book value per share (mrq)0.47

Cash flow statement

Operating cash flow (ttm)-7.61M
Levered free cash flow (ttm)-4.28M